# Novo Nordisk, the pharmaceutical company behind Ozempic, launched an obesity awareness campaign.

*biotech · news · 2026-04-25 · manilastandard.net*

## Key points

- Novo Nordisk officially introduced Wegovy, a weight management drug, to the Philippines last Friday.
- Obesity costs in the Philippines are projected to reach Php 1.9 trillion in 2025, or 7.3% of GDP.
- Wegovy is based on semaglutide, a GLP-1 receptor agonist targeting appetite and metabolic processes.
- Wegovy is not recommended for those with certain thyroid cancers or hypersensitivity to semaglutide.

**Companies:** Novo Nordisk
**Countries:** Philippines

[Read the full story on manilastandard.net](https://manilastandard.net/good-life/314731767/live-lighter-movement-debuts-with-novo-nordisk-obesity-drug.html)

---

Canonical: https://newsio.io/n/0113ee39-0e24-4fd7-be9f-d769c6f4082b/novo-nordisk-the-pharmaceutical-company-behind-ozempic-launched-an-obesity-aware
Summarized by Newsio from manilastandard.net. https://newsio.io/how-it-works